Key result
Administration of calcitriol combined with RAAS inhibitors reduced albuminuria and urinary angiotensinogen levels in patients with type 2 diabetic chronic kidney disease.
Why the study?
Does Vitamin D receptor activation with calcitriol reduce urinary angiotensinogen and albuminuria in patients with type 2 diabetic chronic kidney disease?
Does Vitamin D receptor activation with calcitriol reduce urinary angiotensinogen and albuminuria in patients with type 2 diabetic chronic kidney disease?
Calcitriol combined with RAAS inhibitors may reduce albuminuria in diabetic nephropathy by lowering intra-renal RAAS activity, as reflected by reduced urinary angiotensinogen.
Answers are grounded in this paper and cite their sources.
May support calcitriol adjunct to RAAS inhibitors for albuminuria in diabetic CKD; hypothesis-generating and requires RCT confirmation.
These data indicated that administration of Vitamin D receptor activator in combination with RAAS inhibitors had an additional benefit in lowering albuminuria in patients with DN. More pronounced reduction of urinary albumin:Cr ratio that was positively correlated with angiotensinogen:Cr ratio in calcitriol group suggested that Vitamin D receptor activation might blunt albuminuria by reducing urinary angiotensinogen levels reflecting intra-renal RAAS status.
No takes yet. Share an insight, caveat, or question.
Tiryaki et al. (2015) studied Type 2 diabetic chronic kidney disease (diabetic nephropathy). Calcitriol (Vitamin D receptor activator) combined with RAAS inhibitors was evaluated on Urinary albumin:creatinine ratio and urinary angiotensinogen levels. Administration of calcitriol combined with RAAS inhibitors reduced albuminuria and urinary angiotensinogen levels in patients with type 2 diabetic chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: